Hepatitis C, Indolent B-cell Lymphoma
Conditions
Keywords
hepatitis C, NHL, Indolent B-cell lymphoma
Brief summary
This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).
Detailed description
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated.
Interventions
DRUGLedipasvir+Sofosbuvir
Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg * 12 weeks in previously untreated infected patients * 24 weeks for previously treated patients with uncertain subsequent retreatment options
Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg · 12 weeks of treatment
Sponsors
Fondazione Italiana Linfomi - ETS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>18 years 2. Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular lymphoma grade 1 and 2, CD5-negative B-cell lymphoma NOS 3. HCV-RNA positivity 4. Assessable HCV genotype 5. No previous therapy for the lymphoma 6. Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x 109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in CD5-negative Bcell lymphoma NOS) 7. No need of immediate lymphoma treatment defined as absence of all the following criteria: systemic symptoms, bulky nodal or extranodal mass (\>7 cm), symptomatic splenomegaly, progressive leukemic phase, serous effusions 8. Performance status \<2 according to ECOG scale 9. Adequate hematological counts: ANC \>1 x 109/L, hemoglobin \>9 g/dl (transfusion independent), platelet count \> 50 x 109/L (transfusion independent) 10. No central nervous system (CNS) disease (meningeal and/or brain involvement by lymphoma) 11. Adequate kidney function (creatinine clearance ≥ 45 ml/min) 12. Cardiac ejection fraction ≥45% (echocardiography or MUGA scan) 13. Normal lung function 14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS 15. Non major surgical intervention prior 3 months to enrolment if not due to lymphoma and/or no other disease life-threatening that can compromise chemotherapy treatment 16. Disease free of prior malignancies other than lymphoma for \>3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast 17. Life expectancy \> 6 months 18. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent 19. Written informed consent 20. Women must be: * postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months) * surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), * completely abstinent (at the discretion of the investigator/per local regulations) (periodic abstinence from intercourse is not permitted) or * if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment. 21. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening 22. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug if not taking ribavirin of for 6 months after receiving the last dose of study drug if taking ribavirin.
Exclusion criteria
1. Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma 2. Previous anti-HCV treatment with sustained virological response 3. Diagnosis of cirrhosis (histological or Stiffness \>12 KpA) 4. CNS disease (meningeal and/or brain involvement by lymphoma) 5. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances 6. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug) 7. Concomitant therapy with amiodarone 8. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, 9. Cardiac ejection fraction \<45% (MUGA scan or echocardiography). 10. Creatinine clearance \<45 ml/min 11. Presence of major neurological disorders 12. HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+, HbsAg-, HBsAb+/- patients with HBV-DNA negativity 13. Ongoing systemic bacterial, fungal or viral infections at the time of initiation of study treatment (defined as requiring therapeutic dosing of an antimicrobial, antifungal or antiviral agent) 14. Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or other 15. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast 16. Life expectancy \<6 months 17. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent. 18. If female, the patient is pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SVR12 | 12 weeks from the end of the treatment | Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 36 months | Progression-free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause. |
| EFS | 36 months | Event-free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause |
| OS | 36 months | Overall survival (OS) defined as the time between enrolment and death from any cause |
| ORR for lymphoma | 12 weeks from the end of treatment | ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL) |
| ORR | 12 weeks from the end of treatment | Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment |
| Extended rapid virological response | 4 weeks | extended RVR (eRVR) |
| Early virological response | 4 weeks | early virologic response (EVR) |
| Toxicity - Incidence of Adverse Events | 12 months | toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE). It will be determined by the incidence of severe, life-threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events |
| Rapid virological response | 4 weeks | rapid virologic response (RVR) |
Countries
Italy
Outcome results
None listed